Adam Spitz, an endocrinologist, and Georgina Farrow, a clinical pharmacist, to unpack the science, success stories, safety concerns, and future outlook for GLP-1 medications like Ozempic and Mounjaro for people with T1D
In the NHS, Saxenda should only be prescribed within specialist weight management services according to NICE guidance
The body essentially adapts to the presence of the signaling molecule and requires increasingly higher doses to achieve the same effect
- Scientific American Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Diabetes, Obesity and Metabolism Why are we still in need for novel anti-obesity medications
It's important to do it simultaneously
Cotadutida es un coagonista GLP-1/GCG equilibrado derivado de oxintomodulina de administracin diaria que ha demostrado un moderado efecto reductor de peso en pacientes con diabetes y obesidad, con capacidad de disminuir la fraccin heptica de grasa evaluada mediante densidad protnica por resonancia magntica, as como marcadores de dao heptico y fibrosis51